A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy And Radiation Therapy Alone For Women With Her2- Positive D
Posted Date: May 15, 2019
- Investigator: Jaime Lewis
- Type of Study: Drug
This study will find out if adding trastuzumab to breast radiation therapy is more effective than radiation therapy alone in preventing occurrence of breast cancer in the same breast, in the other breast, or in other parts of the body in patients with HER2-positive Ductal Carcinoma in Situ (DCIS). T
Criteria:
Eligible Patients Must Have Had A Lumpectomy To Remove The Dcis, And Will Be Having Breast Radiation
Keywords:
Breast Cancer, Dcis, Ductal Carcinoma, Her2-Positive, Nsabp B-43
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu